Scientists used transplantation and autochthonous mouse models of PDAC with either genetic tyrosine phosphorylation-regulated kinase 1B (Dyrk1b) loss or pharmacological DYRK1B inhibition, respectively, to investigate whether DYRK1B represented a promising anticancer target in PDAC.
[Gut]
